AHA: CRP screening may not improve CV risk assessments, ASCOT shows
Despite the JUPITER trial that found benefits for assessing patients with a high-sensitivity C-reactive protein (hs-CRP) test, researchers from London found screening for hs-CRP does little or nothing...
View ArticleAHA: Cardiac MR helps outline risks for left ventricular non-compaction
Researchers have found that cardiac MR diagnoses significantly more patients with left ventricular non-compaction, a cardiomyopathy that is associated with heart failure, stroke and ventricular...
View ArticleAHA: Protocol reduces children's rad exposure during EP procedures
A protocol that uses continuous real-time radiation monitoring, low-dose imaging programs and requires physician awareness of radiation dose significantly reduced radiation exposure during...
View ArticleAHA video: ATLAS-ACS: Are thrombins a better target than platelets?
ORLANDOC. Michael Gibson, MD, principal investigator of the ATLAS-ACS trial, sat down with Cardiovascular Business to discuss the rationale and objectives that informed the design of the trial, as well...
View ArticleAHA video: RF ablation may be first-line option for paroxysmal AF
ORLANDO, Fla.Jens Cosedis Nielsen, MD, principal investigator of MANTRA-PAF, spoke with Cardiovascular Business about how the findings from this study could lead to radiofrequency (RF) ablation being...
View ArticleAHA video: Cell therapy finding its niche in cardiac care
ORLANDO, Fla.Jay Traverse, MD, principal investigator of LateTIME, a trial presented Nov. 14 at the American Heart Association (AHA) conference, spoke with Cardiovascular Business about the trial, in...
View ArticleAHA video: Consent reform can make patient informed consumers
ORLANDO, Fla. John Spertus, MD, MPH, principal investigator of the late-breaking clinical trial, PRISM, reviewed a new way to approach the consent form process that allows for greater dialogue between...
View ArticleClik here to view.
AHA video: Remote program as effective as in-person for obesity
ORLANDO, Fla.A weight loss program delivered by health coaches over the phone with website and email support, but no in-person contact was as effective as one delivered in person, the studys lead...
View ArticleAHA: PALLAS shows dronedarone is harmful in permanent AF patients
ORLANDO, Fla.--Based on results from the PALLAS trial, the antiarrhythmic agent dronedarone should not be used as a treatment for patients with permanent atrial fibrillation (AF), the study's chair...
View ArticleAHA: Pharmacist intervention ups prescriptions, but not HF outcomes
ORLANDO, Fla.--A trial of a pharmacist-led intervention in primary care that aimed to optimize preventive heart failure (HF) treatment modestly improved the prescription of lifesaving drugs but did not...
View ArticleAHA video: New trial design for discharged pulmonary embolism patients suggested
ORLANDO, Fla.Samuel Z. Goldhaber, MD, principal investigator of ADOPT, discussed the design and negative findings of the trial, which compared an extended course of thromboprophylaxis with apixaban...
View ArticleAHA: Crestor, Lipitor both shine in high-dose SATURN trial
Both rosuvastatin (Crestor, AstraZeneca) and atorvastin (Lipitor, Pfizer) at maximum dose lowered LDL cholesterol levels, raised HDL levels and reduced atherosclerotic plaque in the SATURN trial, the...
View ArticleAHA video: Kastrati talks ISAR trials, potential bivalirudin uptick in EU
ORLANDO, Fla.Adnan Kastrati, MD, principal investigator of ISAR REACT 4, sat down with Cardiovascular Business to discuss the results of the late-breaking clinical trial presented at the 2011 American...
View ArticleAHA video: Exercise equates to stenting outcomes for PAD
ORLANDO, Fla.CLEVER, a late-breaking clinical trial presented at this years American Heart Association (AHA) scientific sessions, found that for patients with peripheral artery disease (PAD),...
View ArticleAHA video: Critics take high aim at AIM-HIGH; Boden responds
ORLANDO, Fla.AIM-HIGH, a late-breaking clinical trial presented at this years American Heart Association (AHA) scientific sessions, received a great deal of criticism for its design from its...
View ArticleAHA Q&A: Holmes parses out whether ATLAS will change practice
ORLANDO, Fla.When ATLAS-ACS2 was unveiled Nov. 13 at the American Heart Association (AHA) conference, showing a 38 percent reduction in mortality benefit for cardiovascular death with the use of a low...
View ArticleJAMA: Tripling Plavix maintenance dose benefits some poor metabolizers
Patients with stable cardiovascular disease who carry the CYP2C19*2 heterozygotes and were administered 225 mg daily doses of clopidogrel responded at levels seen in noncarriers, according to results...
View ArticleClik here to view.
AHA: Bedside platelet monitoring offers no improvement in outcomes
Patients who received platelet function monitoring and dose adjustments after stent implantation fared no better than those given standard care, according to a study published online Nov. 4 in the New...
View ArticleClik here to view.
AHA: CABG bests PCI for diabetics with multivessel disease, but not for stroke
For diabetic patients with multivessel disease, CABG was superior to PCI in that it significantly reduced rates of death and MI, but had a higher risk of stroke, based on the late-breaking FREEDOM...
View ArticleClik here to view.
AHA: Aspirin’s latest laurel: Preventing recurrent venous thromboembolism
Evidence is tipping in favor of aspirin for long-term prevention of recurrent venous thromboembolism in high-risk patients. While the ASPIRE trial found no significant reduction in the rate of late...
View Article
